Amphivena Therapeutics, Inc.

- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.amphivena.com
Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Study of AMV564 in Subjects With Advanced Solid Tumors
- Conditions
- Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2021-10-19
- Lead Sponsor
- Amphivena Therapeutics, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT04128423
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸Advent Health, Orlando, Florida, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes
- Conditions
- Myelodysplastic Syndrome (MDS)
- Interventions
- Drug: AMV564 14-Day CIV
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Amphivena Therapeutics, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT03516591
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Washington University, Siteman Cancer Center, Saint Louis, Missouri, United States
Study of AMV564 in Patients With AML
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2017-05-08
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Amphivena Therapeutics, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT03144245
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Northwestern, Chicago, Illinois, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States